title: Screening adolescents and young women.
abstract: Recent guidelines from multiple organizations stress screening initiation no earlier than the age of 21 years and increased screening intervals for women aged 21 to 29 years. Primary prevention with human papillomavirus vaccination has the potential to significantly affect the development of high-grade cervical lesions, including cancer, and will likely affect screening guidelines in the future.
authors.affiliation: Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827, USA. Lori.Boardman@ucf.edu
authors.forename: Lori A
authors.initials: LA
authors.lastname: Boardman
authors.forename: Katina
authors.initials: K
authors.lastname: Robison
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003127:Colposcopy / Q000009:adverse effects; D032921:Consensus; D003906:Developing Countries / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000639:trends; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000517:prevention & control / Q000635:transmission; D053918:Papillomavirus Vaccines; D017410:Practice Guidelines as Topic; D012749:Sexually Transmitted Diseases; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000517:prevention & control* / Q000821:virology; D014626:Vaginal Smears; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000473:pathology / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines